Proactive Investors - Run By Investors For Investors

BARD1 Life Sciences Ltd targets cash injection

The halt will remain in place until Wednesday 5th July 2017.
BARD1 Life Sciences Ltd targets cash injection
BARD1 is focused on tests for cancer

BARD1 Life Sciences Ltd (ASX:BD1) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The company is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

The halt will remain in place until the opening of trade on Wednesday 5th July 2017, or earlier if an announcement is made to the market.

View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
A doctor's stethoscope and a marijuana plant
February 23 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use